Low-dose zoledronic acid reduces spinal cord metastasis in pulmonary adenocarcinoma with neuroendocrine differentiation

Ying Ying Li, John W C Chang, Ling Ling Hsieh, Shu Mei Chen, Kun Yun Yeh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Zoledronic acid (ZOL), a nitrogen-containing compound, is effective in the treatment of skeletal disorders, but its long-term use in high doses gives rise to complications such as osteonecrosis. We aimed to investigate the effect of low-dose ZOL on the expression of the neural cell adhesion molecule (NCAM), which may be correlated with tumor growth and spinal cord metastasis in lung adenocarcinoma with neuroendocrine differentiation. First, we used the small hairpin RNA technique to directly knock down NCAM expression in cells of a murine lung adenocarcinoma line, line 1 cells, and found that the tumor cells generated showed lower invasive capacity, slower tumor growth, and lesser tendency for spinal cord metastasis than control cells. Further, ZOL decreased NCAM expression and invasiveness in line 1 tumor cells in vitro. Line 1/lacZ cells, a stable clone tagged with the lacZ gene, were introduced into mice, followed by ZOL treatment (1 μg/kg/weekly). Low-dose ZOL significantly reduced spinal cord metastasis probably through reduced NCAM expression in vivo. These findings indicated that NCAM is involved in tumor growth and spinal cord metastasis of lung adenocarcinoma with neuroendocrine differentiation. Treatment with low-dose ZOL can reduce NCAM expression that may contribute toward reduced spinal cord metastasis, suggesting that NCAM is an alternative therapeutic target and that the low-dose ZOL treatment protocol is a reasonable approach for its treatment.

Original languageEnglish
Pages (from-to)970-978
Number of pages9
JournalAnti-Cancer Drugs
Volume23
Issue number9
DOIs
Publication statusPublished - Oct 1 2012
Externally publishedYes

Fingerprint

zoledronic acid
Neural Cell Adhesion Molecules
Spinal Cord
Neoplasm Metastasis
Spinal Cord Neoplasms
Growth
Nitrogen Compounds
Therapeutics
Lac Operon
Osteonecrosis
Clinical Protocols
Adenocarcinoma of lung
Tumor Cell Line
Small Interfering RNA
Neoplasms

Keywords

  • lung adenocarcinoma
  • neural cell adhesion molecule
  • neuroendocrine differentiation
  • spinal cord metastasis
  • zoledronic acid

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Low-dose zoledronic acid reduces spinal cord metastasis in pulmonary adenocarcinoma with neuroendocrine differentiation. / Li, Ying Ying; Chang, John W C; Hsieh, Ling Ling; Chen, Shu Mei; Yeh, Kun Yun.

In: Anti-Cancer Drugs, Vol. 23, No. 9, 01.10.2012, p. 970-978.

Research output: Contribution to journalArticle

Li, Ying Ying ; Chang, John W C ; Hsieh, Ling Ling ; Chen, Shu Mei ; Yeh, Kun Yun. / Low-dose zoledronic acid reduces spinal cord metastasis in pulmonary adenocarcinoma with neuroendocrine differentiation. In: Anti-Cancer Drugs. 2012 ; Vol. 23, No. 9. pp. 970-978.
@article{bec2f8615cc04ba6a6ba961e5a2a4f1e,
title = "Low-dose zoledronic acid reduces spinal cord metastasis in pulmonary adenocarcinoma with neuroendocrine differentiation",
abstract = "Zoledronic acid (ZOL), a nitrogen-containing compound, is effective in the treatment of skeletal disorders, but its long-term use in high doses gives rise to complications such as osteonecrosis. We aimed to investigate the effect of low-dose ZOL on the expression of the neural cell adhesion molecule (NCAM), which may be correlated with tumor growth and spinal cord metastasis in lung adenocarcinoma with neuroendocrine differentiation. First, we used the small hairpin RNA technique to directly knock down NCAM expression in cells of a murine lung adenocarcinoma line, line 1 cells, and found that the tumor cells generated showed lower invasive capacity, slower tumor growth, and lesser tendency for spinal cord metastasis than control cells. Further, ZOL decreased NCAM expression and invasiveness in line 1 tumor cells in vitro. Line 1/lacZ cells, a stable clone tagged with the lacZ gene, were introduced into mice, followed by ZOL treatment (1 μg/kg/weekly). Low-dose ZOL significantly reduced spinal cord metastasis probably through reduced NCAM expression in vivo. These findings indicated that NCAM is involved in tumor growth and spinal cord metastasis of lung adenocarcinoma with neuroendocrine differentiation. Treatment with low-dose ZOL can reduce NCAM expression that may contribute toward reduced spinal cord metastasis, suggesting that NCAM is an alternative therapeutic target and that the low-dose ZOL treatment protocol is a reasonable approach for its treatment.",
keywords = "lung adenocarcinoma, neural cell adhesion molecule, neuroendocrine differentiation, spinal cord metastasis, zoledronic acid",
author = "Li, {Ying Ying} and Chang, {John W C} and Hsieh, {Ling Ling} and Chen, {Shu Mei} and Yeh, {Kun Yun}",
year = "2012",
month = "10",
day = "1",
doi = "10.1097/CAD.0b013e328355f0ec",
language = "English",
volume = "23",
pages = "970--978",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Low-dose zoledronic acid reduces spinal cord metastasis in pulmonary adenocarcinoma with neuroendocrine differentiation

AU - Li, Ying Ying

AU - Chang, John W C

AU - Hsieh, Ling Ling

AU - Chen, Shu Mei

AU - Yeh, Kun Yun

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Zoledronic acid (ZOL), a nitrogen-containing compound, is effective in the treatment of skeletal disorders, but its long-term use in high doses gives rise to complications such as osteonecrosis. We aimed to investigate the effect of low-dose ZOL on the expression of the neural cell adhesion molecule (NCAM), which may be correlated with tumor growth and spinal cord metastasis in lung adenocarcinoma with neuroendocrine differentiation. First, we used the small hairpin RNA technique to directly knock down NCAM expression in cells of a murine lung adenocarcinoma line, line 1 cells, and found that the tumor cells generated showed lower invasive capacity, slower tumor growth, and lesser tendency for spinal cord metastasis than control cells. Further, ZOL decreased NCAM expression and invasiveness in line 1 tumor cells in vitro. Line 1/lacZ cells, a stable clone tagged with the lacZ gene, were introduced into mice, followed by ZOL treatment (1 μg/kg/weekly). Low-dose ZOL significantly reduced spinal cord metastasis probably through reduced NCAM expression in vivo. These findings indicated that NCAM is involved in tumor growth and spinal cord metastasis of lung adenocarcinoma with neuroendocrine differentiation. Treatment with low-dose ZOL can reduce NCAM expression that may contribute toward reduced spinal cord metastasis, suggesting that NCAM is an alternative therapeutic target and that the low-dose ZOL treatment protocol is a reasonable approach for its treatment.

AB - Zoledronic acid (ZOL), a nitrogen-containing compound, is effective in the treatment of skeletal disorders, but its long-term use in high doses gives rise to complications such as osteonecrosis. We aimed to investigate the effect of low-dose ZOL on the expression of the neural cell adhesion molecule (NCAM), which may be correlated with tumor growth and spinal cord metastasis in lung adenocarcinoma with neuroendocrine differentiation. First, we used the small hairpin RNA technique to directly knock down NCAM expression in cells of a murine lung adenocarcinoma line, line 1 cells, and found that the tumor cells generated showed lower invasive capacity, slower tumor growth, and lesser tendency for spinal cord metastasis than control cells. Further, ZOL decreased NCAM expression and invasiveness in line 1 tumor cells in vitro. Line 1/lacZ cells, a stable clone tagged with the lacZ gene, were introduced into mice, followed by ZOL treatment (1 μg/kg/weekly). Low-dose ZOL significantly reduced spinal cord metastasis probably through reduced NCAM expression in vivo. These findings indicated that NCAM is involved in tumor growth and spinal cord metastasis of lung adenocarcinoma with neuroendocrine differentiation. Treatment with low-dose ZOL can reduce NCAM expression that may contribute toward reduced spinal cord metastasis, suggesting that NCAM is an alternative therapeutic target and that the low-dose ZOL treatment protocol is a reasonable approach for its treatment.

KW - lung adenocarcinoma

KW - neural cell adhesion molecule

KW - neuroendocrine differentiation

KW - spinal cord metastasis

KW - zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84865961769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865961769&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e328355f0ec

DO - 10.1097/CAD.0b013e328355f0ec

M3 - Article

C2 - 22713592

AN - SCOPUS:84865961769

VL - 23

SP - 970

EP - 978

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 9

ER -